Updates on SINEMET® (levodopa and carbidopa) Shortages

and Discontinuation of SINEMET® CR in Canada

April 5, 2019

Merck & Co. (known as MSD internationally) has informed regulatory health agencies that they continue to experience supply constraints SINEMET® (levodopa and carbidopa) and SINEMET® CR emanating from manufacturing challenges and delays with a third-party supplier.  Supply disruptions are expected to continue throughout 2019.


For SINEMET® CR Merck Canada regrets to announce that after having unsuccessfully pursued alternative supply options, the difficult decision was made to cease the manufacturing, distribution and supply of this particular product once all current inventories have been exhausted.


As of April 4th, the status of product supply is as follows:


Product Name
Anticipated Out of Stock Date
Anticipated Resupply
SINEMET® 100mg/25mg
November 16, 2018
July 2020
SINEMET® 250mg/25mg
December 2019
July 2020
SINEMET® CR 100mg/25mg
Remaining supply projected to last until September 2019
No Resupply
SINEMET® CR 200mg/50mg
February 28, 2019 (anticipated)
No Resupply


In speaking with some of our Alberta neurologists, it was noted that because of the shortages that have already existed, many patients were already taking the generic alternatives.  A generic alternative is available to those with current prescriptions; speak with your neurologist, GP or pharmacist to find out what options may be available to you.


The most up-to-date information regarding SINEMET® supply details is available at www.drugshortagescanada.ca.
Top of Page